drugset / Trial / NCT05849272

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

NCT05849272

Phase 4 Completed 60 enrolled Shanghai Mental Health Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of somatic symptoms in depression, to provide evidence-based basis for clinical rational drug use.

Timeline

Start
2023-05-12
Primary completion
2024-05-08
Completion
2024-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Toludesvenlafaxine Small molecule 80 mg Oral
Subject Toludesvenlafaxine Small molecule 160 mg Oral

Indications